Working… Menu

PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00511043
Recruitment Status : Terminated (Manufacturer stopped drug development)
First Posted : August 3, 2007
Last Update Posted : December 9, 2014
Novartis Pharmaceuticals
Information provided by (Responsible Party):
David Rizzieri, MD, Duke University

Brief Summary:
This is a phase II open label study to assess the efficacy and safety of PTK787/ZK222584 in adults with relapsed or refractory diffuse large cell lymphoma (DLCL). All subjects will receive PTK787/ZK222584. Subjects who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or non-compliance with the protocol requirement.

Condition or disease Intervention/treatment Phase
Lymphoma, Large-Cell, Diffuse Drug: PTK787 Phase 2

Detailed Description:

In order for tumors to grow and spread to other parts of the body, they need to have a growing blood supply. Tumor cells have been shown to produce substances that stimulate the abnormal growth of new blood vessels that allow the tumor to grow. In adults, blood vessel cells normally divide very rapidly. It is thought that PTK787/ZK222584 may interfere with the growth of new blood vessels. A drug that interferes with the growth of new blood vessels might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Since normal blood vessel cells divide very rapidly, it might be possible to stop tumor growth without harming normal tissues.

The purpose of this study is to find out if an investigational drug, PTK787/ZK 222584 is safe and effective in treating relapsed or refractory diffuse large cell lymphoma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Open Label Study of PTK787/ZK222584 in Adults Patients With Refractory or Relapsed Diffuse Large Cell Lymphoma
Study Start Date : November 2005
Actual Primary Completion Date : August 2009
Actual Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: All pts
Drug: PTK787
PTK787 - 1250mg p.o. daily. Initial dose of 750mg p.o daily starting on day 1 and increased weekly to an intermediate dose of 1000 mg and then a target dose of 1250mg unless a grade ≥ 2 toxicity. Patients who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or patient non-compliance with the protocol requirement.
Other Names:
  • Vatalanib
  • ZK 222584
  • PTK787/ZK 222584

Primary Outcome Measures :
  1. Response [ Time Frame: approximately 1 year ]

Secondary Outcome Measures :
  1. Safety [ Time Frame: 30 days post last dose of study drug ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed DLCL (de novo or transformed).
  • Measurable/evaluable disease by radiographs, physical exam or bone marrow involvement.
  • Refractory disease, induction chemotherapy failure or relapsed disease.
  • Age ≥ 18 years old
  • Performance Status:KPS ≥ 70
  • Laboratory tests as specified by the protocol.
  • Written informed consent

Exclusion Criteria:

  • History of known central nervous system disease (i.e., primary brain tumor, malignant seizures, CNS metastases or carcinomatous meningitis).
  • History of another primary malignancy ≤ 5 years, with the exception of inactive basal or squamous cell carcinoma of the skin
  • Prior chemotherapy ≤ 3 weeks prior to registration. There is no limit to the number of prior chemotherapy regimens.
  • Prior allogeneic transplant if >2.5% donor cells remain by engraftment studies (prior autologous transplant is allowed)
  • Prior biologic or immunotherapy ≤ 2 weeks prior to registration.
  • Prior full field (total organ site) radiotherapy ≤ 4 weeks or limited field radiotherapy ≤ 2 weeks prior to registration.
  • Major surgery (i.e., laparotomy) ≤ 4 weeks prior to registration. Minor surgery ≤ 2 weeks prior to registration.
  • Patients who have received investigational drugs ≤ 4 weeks prior to registration and/or registration
  • Prior therapy with anti-VEGF targeted agents
  • Pleural effusion or ascites that causes respiratory compromise (≥ CTC grade 2 dyspnea)
  • QTc > 450 (male) or > 470 (female). Patients with congenital or acquired prolonged QTc syndrome
  • Female patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control.
  • Any of the following concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study:

    • Uncontrolled high blood pressure, history of labile hypertension, or history of poor compliance with an antihypertensive regimen
    • Unstable angina pectoris
    • Symptomatic congestive heart failure
    • Myocardial infarction ≤ 6 months prior to registration
    • Serious uncontrolled cardiac arrhythmia
    • Uncontrolled diabetes
    • Severe active or uncontrolled infection
    • Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
  • Chronic renal disease with documented nephritic or nephrotic syndrome.
  • Acute or chronic liver disease
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of PTK787/ZK222584
  • Patients with confirmed diagnosis of human immunodeficiency virus (HIV) infection are excluded at the investigator's discretion if he/she feels that 1) a potential drug interaction between PTK787/ZK 222584 and anti-HIV medications that could influence the efficacy of the anti-HIV medication, or 2) it may place the patient at risk due to the pharmacologic activity of PTK787/ZK 222584.
  • Patients who are taking therapeutic warfarin sodium (Coumadin) or similar oral anticoagulants that are metabolized by the cytochrome P450 system.
  • Patients unwilling to or unable to comply with the protocol
  • Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and in the judgment of the investigator would make the patient inappropriate for entry into this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00511043

Layout table for location information
United States, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
South Carolina Oncology Associates
Columbia, North Carolina, United States, 29210
Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
David Rizzieri, MD
Novartis Pharmaceuticals
Layout table for investigator information
Principal Investigator: David A Rizzieri, MD Duke University
Layout table for additonal information
Responsible Party: David Rizzieri, MD, Associate Professor of Medicine, Division of Cellular Therapy, Duke University Identifier: NCT00511043    
Other Study ID Numbers: Pro00008648
7416 ( Other Identifier: Legacy Duke IRB number )
First Posted: August 3, 2007    Key Record Dates
Last Update Posted: December 9, 2014
Last Verified: November 2014
Keywords provided by David Rizzieri, MD, Duke University:
Diffuse large cell lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action